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Background: Randomized controlled trials (RCTs) often have more than one primary outcome and frequently have
secondary and harm outcomes. Comparison of outcomes between study arms is the primary focus of RCTs, but
there are times when the relation between outcomes is important, such as determining whether an intermediate
outcome and a clinical outcome have a strong association. We sought to determine how often reports of RCTs
depict the relations among outcomes at the individual patient level and, for those studies that use composite
outcomes, how often the relations between component elements are depicted.
Methods: We selected 20 general, specialty and subspecialty medical journals with high impact factors that publish
original clinical research. We identified every RCT in the 2011 and 2012 issues and randomly selected 10 articles per
journal. For each article we recorded the number of outcomes, the number of composite outcomes and how often
the relations between outcomes or elements of composite outcomes were portrayed.
Results: All but 16 of the 200 RCTs had more than one outcome. Thus, outcomes could have been related in
92% of studies, but such relations were only reported in 2 (1%). A total of 33 (17%) investigations measured a
composite outcome, 32 of which showed data for each component. None, however, showed cross-tabulation of
the components.
Conclusions: Readers are rarely shown the relation between outcomes. Mandatory posting of datasets or
requirements for detailed appendices would allow readers to see these cross-tabulations, helping future
investigators know which outcomes are redundant, which provide unique information and which are most
responsive to changes in the independent variables. While not every relationship between outcomes requires
depiction, at present such information is seldom portrayed.
Keywords: Journalology, Clinical trials, Reporting guidelines, Clinical outcomesBackground
Ethical considerations mandate that maximal use is
made from the data obtained in randomized trials of
humans and animals [1-3]. While many have called for
the public availability of all such data, concerns about
patient confidentiality and investigator reluctance to
cede control of the data they worked hard to collect,
have made progress in this direction slow. There are,
however, many ways to share more data within a trad-
itional publication format that are not currently being
fully exploited. Only a fraction of available data about
trial outcomes is conveyed in the typical trial report [4],* Correspondence: schriger@ucla.edu
1Department of Emergency Medicine, University of California, 924 Westwood
Blvd, Suite 300, Los Angeles, CA 90024, USA
Full list of author information is available at the end of the article
© 2015 Schriger et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.a problem that can be lessened by including better ta-
bles and figures [5,6].
We have noticed that studies that report on several
outcomes seldom provide information on the relation
between these outcomes. Similarly, studies that use com-
posite outcomes seldom compare the elements of the
composite at the level of the individual. There are cir-
cumstances when this could be desirable. For example,
future researchers may wish to know how well an easily
or inexpensively obtained secondary outcome relates to
a more clinically important, patient-centered outcome
that is more difficult or costly to obtain. Such knowledge
could help in the selection of outcomes in future trials.
Knowledge of such relationships at the individual level
can also be useful in providing construct validity to al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Schriger et al. Trials  (2015) 16:57 Page 2 of 6trial and helping investigators understand the mecha-
nisms by which an intervention works. The conclusions
of a pediatric asthma study that showed that one in-
haler reduced days missed from school (the primary
clinical outcome) more than another would be different
if there was a strong negative correlation between days
missed from school and improvement in forced expira-
tory volume (FEV-1) than if there was a strong positive
correlation. The latter would suggest that improvement
in airflow was not on the causal pathway from inhaler
use to better school attendance, requiring investigators
to check their data for bias or to revise their theoretical
model.
We conducted this study to determine how often in-
vestigators reported the relationship between outcomes
in their studies for both individual outcomes and for the
components of composite outcomes.
Methods
Study design
We performed a cross-sectional survey of randomized
controlled trials (RCTs) published in 20 general medical,
specialty and subspecialty journals with high impact fac-
tors between 2011 and 2012.
Selection of journals
We chose the top journals based on the 2011 Journal
Citation Reports Impact Factor [7], selecting journals
that publish original clinical research in English and
excluding those that publish only review articles or
predominantly basic science research. We selected the
six highest ranked general medical journals, the high-
est ranked journal in seven specialties and the highest
ranked journal in seven randomly selected medical and
surgical subspecialties (list of journals in Additional
file 1: Table S1).
Selection of articles within journals
We identified every RCT in the 2011 and 2012 issues of
each journal by searching MEDLINE for publication type
‘Randomized Controlled Trial’ or a title with ‘random*’.
For each journal we generated a randomly ordered list
of RCTs and selected the first 10 that were primary re-
ports of studies of at least 40 humans. We used a separ-
ate sample of 20 RCTs from 2012 issues of general
medical journals to develop and refine the data collec-
tion and coding rules.
Data abstraction
We reviewed the entire RCT report including all print
and online supplements and appendices using a data col-
lection instrument we developed for this study. After de-
veloping a preliminary scoring form and coding manual,
four authors each independently coded 10 RCTs and metto refine variable definitions and coding rules. Two
authors then scored another 10 RCTs, inter-rater re-
liability was assessed and rules were further revised.
These authors then each scored half of the 200 RCTs
included in the final data set. Both raters independently
scored 10 papers as a final formal measure of inter-rater
reliability.
Variable definition
The data form contained entries for: the number of pri-
mary, secondary and harm outcomes reported in the
study; the number of composite outcomes and whether
components were separately reported; and the number
of outcomes and components that were compared to
each other at the subject level.
For each RCT we determined if the authors either ex-
plicitly (‘the primary outcome was…’) or implicitly (for
example ‘we based our sample size on …’) identified a
primary outcome, and if so, how many outcomes were
identified as ‘primary’. We also counted the number of
secondary outcomes and the number of harm outcomes,
considering an outcome as a ‘harm’ whenever the authors
or context deemed it so. Any outcome not categorized as
primary or harm was considered secondary, unless there
were no explicitly or implicitly stated primary outcomes,
in which case all non-harm outcomes were considered
primary.
To avoid over-counting, if several secondary outcome
variables each measuring aspects of the same construct
(for example FEV-1, peak flow and minute ventilation,
all measuring airflow) were measured at multiple times
(for example at four different times), we did not count
this as 12 secondary outcomes but instead counted ei-
ther the number of variables (three in this case) or the
number of measurements of each variable (four), which-
ever was the larger number (four in this example). When
investigators grouped harms either by severity (for example
mild versus moderate versus severe) or organ system (for
example cardiac or pulmonary) or another rubric, we
counted the number of categories rather than the num-
ber of individual harm variables. Having identified and
enumerated all primary, secondary and harm outcomes,
we then identified any comparison or cross-tabulation
of the outcomes at the subject level, and categorized
each as primary versus primary, primary versus secon-
dary, primary versus harm and so forth.
Primary analysis
Our analysis was descriptive. The unit of analysis was the
research paper, and our primary outcome was the number
of articles reporting a relationship among outcomes, by
which we mean any graph, table or text that provided an
indication of how one outcome variable related to another
at the individual patient level. Data were collected in a
Table 1 Outcome reporting in 200 randomized trials
Trial outcomes (n = 200)
Primary outcome stated explicitly 198
Number of primary outcomes: mean, median,
(range) (IQR)
2.2, 1, (1, 19) (1, 3)
Papers with one primary outcome: N (%) 114 (57%)
Number of secondary outcomes: mean, median,
(range) (IQR)
3.8, 3, (0, 25) (0, 5)
Number of harms: mean, median, (range) (IQR) 2.4, 0, (0, 21) (0, 3)
Papers with more than one outcome: N (%) 184 (92%)
Comparisons among outcomes (n = 184)
Number of papers with comparisons between
outcomes
2
Total number of comparisons between outcomes 28
Type of comparison
Primary versus primary 1
Primary versus secondary 11
Primary versus harm 6
Secondary versus secondary 4
Secondary versus harm 6
Harm versus harm 0
Composite primary outcomes: N (%) 33 (17%)
Number of items in composites: mean, median
(range) (IQR)
4.7, 3, (2, 21) (2, 5)
Number of papers showing individual elements:
N (%)
32/33 (97%)
Number of individual elements shown: N (%) 152/155 (98%)
Individual elements compared to other
individual elements
0
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and analyses were performed with Stata 12 software (Stata
Corp, College Station, Texas, United States). We re-
corded each journal’s impact factor and whether the
journal endorsed the Consolidated Standards of Report-
ing Trials (CONSORT) reporting guidelines by review-
ing their Instructions for Authors and journal website
information [8].
Post hoc analysis
Trials peer reviewers suggested that the comparisons
we sought might be presented in secondary trial publi-
cations rather than the main publication of the trial. To
examine this hypothesis we randomly selected one article
per journal from our 200 article database and checked
MEDLINE for papers citing the article. We then checked
these citations to see if any were secondary reports of the
original RCT and, if so, if they contrasted any of the out-
comes from the primary study.
Results
The 2011 impact factor of the 20 journals in our study
ranged from 3.3 to 53.3. All but one endorsed the
CONSORT statement. (Additional file 1: Table S1) We
reviewed 224 articles to identify the 200 articles (10 per
journal) in our sample. We excluded 24 articles (16 that
were not primary reports of RCTs, four research letters,
one pilot study (<40 subjects), one nonhuman subjects,
one cost analysis of an RCT and one editorial). The final
round of inter-rater reliability of abstraction achieved
100% agreement on all items except the number of harms
(80%, eight out of 10). After clarifying the scoring rule, the
harm items in the 10 articles were rescored and agreement
was 100%; raters then rescored the harm items in all arti-
cles they had scored in order to ensure consistency.
All but two studies identified a primary outcome; in
one the authors stated that they intentionally avoided
considering any of the 11 outcomes primary, in the
other there were six outcomes and no comment regard-
ing which was primary [9,10]. While the word primary
implies that there would be a single most important
outcome, the CONSORT statement recommends a sin-
gle primary outcome and study size calculations are al-
most always based on a single outcome, 43% (86 out of
200) of articles had more than one primary outcome
[11]. The mean number of primary outcomes was 2.2
(median: 1, range: 1 to 19) (Table 1, Figure 1A). A total
of 134 (67%) studies reported secondary outcomes and
64 (32%) reported harms. Across all studies, a mean of
3.8 secondary outcomes and 2.4 harms were reported.
(Figure 1B, C). Studies that reported at least one secon-
dary outcome reported a mean of 5.7 (median: 4, range:
1 to 25). For harms these numbers were 7.3 (median: 6,
range: 1 to 21).Among the 184 (92%) studies that reported more than
one outcome, only two (1%) presented the relationship
between outcomes. These two articles reported 28 differ-
ent relationships (Table 1). One article in the American
Journal of Psychiatry was a placebo controlled trial of
metformin to reverse amenorrhea in schizophrenics [12].
The primary outcome measures were: the percentage of
women who had restoration of menstruation, change in
body weight and change in Body Mass Index (BMI). The
secondary measures were several hormone levels and a
symptom score, the Positive and Negative Syndrome Scale
(PANSS). In addition to reporting outcome measures for
each group, the authors performed a logistic regression to
examine whether changes in body weight and BMI (both
primary outcomes) and five hormone levels (secondary
outcomes) were predictive of return of menstruation (pri-
mary outcome). By so doing they attempted to elucidate
the mechanism by which metformin might help restore
menstruation.
The second paper, in The Lancet, reported an RCT
comparing defibrotide and no treatment for the pre-
vention of hepatic veno-occlusive disease in children
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Figure 1 Histogram of the number of outcomes reported in the
200 randomized controlled trials. (A) Primary outcomes; (B)
Secondary outcomes; (C) Harm outcomes. Solid red line =median.
Dashed red line = mean.
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come was the occurrence of a hepatic veno-occlusive
event in the 30 days post-transplant. Secondary out-
comes included 100 and 180-day mortality, multiorgan
failure and graph versus host disease. Harm outcomes
included sepsis and cardiovascular and pulmonary compli-
cations. The relationships among these variables werepresented in a supplementary table which contained 26
comparisons (10 primary versus secondary, four second-
ary versus secondary, six harm versus primary and six
harm versus secondary).
A total of 17% of the RCTs (33 out of 200) repor-
ted a composite outcome, with a mean of 4.7 elements
(median: 3, range: 2 to 21) per composite. All but one
article (97%, 32 out of 33) reported results for the indi-
vidual elements of the composite (152 of 155 elements).
None of the articles depicted the relationship among
components.
In our post hoc analysis we found that 14 of the 20 ori-
ginal trial reports had no secondary publications. For the
six trials with secondary publications, none contained
contrasts among outcome variables. While it is likely that
we would find a few comparisons in secondary studies of
the 180 trials we did not check for secondary publications,
their numbers will be insufficient to change our conclu-
sions, and it did not seem worth the effort to check the
other 180 papers in the name of completeness.
Discussion
Our study demonstrates that authors almost never (1%)
present the relationship between outcomes of random-
ized trials in primary reports in medical journals with
high impact factors. We did not attempt to score how
often this truly represented a ‘missed opportunity’ as this
concept is highly subjective and is dependent on the
reader and context. Nevertheless, there are certainly some
papers for which some readers would have been interested
in the relationship among outcome variables at the patient
level. Such relations could be reported in an online-only
appendix so they are available to the interested reader but
are not distracting to others. As noted in our Background
section, an understanding of such relationships can assist
in the selection of outcome measures for future research,
provide construct validity (for example, when biomarkers
relate to clinical outcomes in expected ways) and provide
insight into the mechanism of action of an intervention
(as in the aforementioned American Journal of Psychiatry
paper). We note, however, that care is needed in conduc-
ting and interpreting relationships between outcomes
within a trial. Our focus has been on associations. For ana-
lyses relating intermediate outcomes to final outcomes,
however, there may be a temptation to seek a causal ex-
planation. Such inference requires complex consider-
ations, beyond the scope of this paper [14]. For example,
misinterpretation is likely when relating a clinical outcome
to compliance with therapy or to tumor response in
cancer trials [15,16].
It is difficult to identify articles that contrast outcomes
using MEDLINE as there are no MeSH (Medical Subject
Heading) or study design terms that can be used to flag
such papers. We had better results searching Google
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change’, a strategy that identified a number of articles
that contrasted outcomes. Many of these articles were
secondary analyses of larger trials; studies that would
not have been included in our primary study [17-19].
Others were exactly what we envisioned. Lapperre et al.
compared treatments for chronic obstructive pulmonary
disease (COPD) in smokers measuring both inflamma-
tory cell counts and intermediate clinical outcomes [20].
Their figure four contrasts these outcomes, and shows
that changes in cluster of differentiation 4 (CD4) and
mast cell counts are poorly correlated with changes in
FEV-1 and methacholine challenge [20]. Krasner et al.
provided primary care physicians with a mindfulness
education program, conducting assessments of mindful-
ness, burnout, empathy and psychosocial orientation
and mood, before and several times after the intervention
[21]. They compared these different outcomes using
correlation (their table four) and demonstrated that an
increase in mindfulness was associated with a decrease
in burnout scores and mood disturbance scales and an
increase in the quality of empathy [21]. In a secondary
analysis of the CLEVER (Claudication: Exercise Vs. Endo-
luminal Revascularization) trial, Murphy et al. compared
revascularization and supervised exercise for the treat-
ment of leg claudication and demonstrated that the degree
of correlation between clinical outcomes is different in the
two treatment groups, a very important finding for those
doing research in this field [17].
For composite outcomes, an understanding of the rela-
tionship among the components at the by-subject level
may be as important as knowing the frequency of each
component. All but one journal in our study endorsed
CONSORT, but CONSORT does not mention this aspect
of trial reporting [8]. If the CONSORT group decide that
authors should depict the relationships among key out-
comes, then the addition of an item to the CONSORT
document would likely increase this aspect of trial report-
ing. Many have called for more transparency in the report-
ing of clinical trials, including the electronic posting of
data sets so that researchers can fully evaluate authors’
claims and make full use of the data [1-3]. Until such time
as this practice becomes routine, depiction of the relation-
ships between trial outcome measures in supplementary
tables and figures may help to maximize the information
gained from these trials.
We evaluated articles in journals with high impact fac-
tors; results in other journals may differ. There is little
reason to believe that relationships between outcomes
would be more frequently reported in such journals. We
evaluated only 10 articles per journal, a number too
small to ensure stable estimates for each journal. While
our overall estimate of 1% may be somewhat imprecise,
our conclusion, that such depictions are rare, is not atrisk. Finally, we did not evaluate secondary reports of all
the RCTs. It is conceivable that there were some rela-
tionships among outcomes presented there.
Conclusions
Authors seldom present comparison of trial outcomes, a
practice that is quite important in selected circumstances.
This finding is yet another demonstration of the clinical
research community’s failure to fully utilize the data gen-
erated from clinical trials: a breakdown in the moral con-
tract between researchers and the patients who consent to
participate in such activities.
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